Cost-effectiveness and economic impact of the KineSpring® Knee Implant System in the treatment of knee osteoarthritis in the United Kingdom.
Knee osteoarthritis (OA) is a condition affecting 8.5 million individuals in the United Kingdom (UK). Although many treatment options are available, there is a need for a less-invasive treatment for individuals with mild to moderate knee OA. The purpose of the present study was to determine whether the KineSpring System is a more effective treatment for knee OA when compared to other standard treatments, taking into consideration cost-utility ratios. Data was collected for the UK population breakdown. A literature search provided data on conservative and surgical treatment costs and functional outcome scores. The KineSpring System outcome scores were obtained from two trials. Quality-adjusted life years (QALYs) gained and cost-utility ratios were calculated for each treatment option, assuming a lifetime durability as well as 10-year durability. Assuming lifetime durability, the cost-utility ratios of surgical treatment, total knee arthroplasty (TKA), the KineSpring System, and conservative treatments, compared to no treatment are £1,303±22/QALY, £821±175/QALY, £796±73/QALY and £11,096±1188/QALY, respectively. Assuming a treatment durability of 10 years, the cost-utility ratio of surgical treatment, TKA, the KineSpring System, and conservative treatments, compared to no treatment are £4,153±95 per QALY, £2,698±768 per QALY, £2,848±345 per QALY, and £10,624±1528 per QALY, respectively. This study demonstrates that the KineSpring System is a cost-effective treatment for knee OA and is comparable to current standard-of-care treatments. Further research is needed to assess the long-term outcomes associated with the KineSpring System.